The effect of oral pioglitazone on the expression of genes for fat and glucose metabolism in fatty liver induced rats

Abstract

Pioglitazone is one of the drugs used to treat diabetes and fatty liver In this study, the effect of this drug on the expression of genes of fat and glucose metabolism in rats with fatty liver induced in this study was investigated. The effect of the drug on FATP5, CD36, LXRα, FATP5 genes in the pathway of fat metabolism and GYS gene in the pathway of glucose metabolism was investigated Materials and Methods: Male Wistar rats were divided into four groups of ten including healthy control, fatty liver control, fatty liver without drug treatment and fatty liver with drug treatment. Fatty liver in mice was developed by a high-fat diet formulated after 8 weeks. Fatty liver was confirmed by staining with hematoxin eosin and by observing cells full of fat droplets. Fatty liver was confirmed by staining with hematoxin eosin and by observing cells full of fat droplets. Treatment with oral pioglitazone was done by gavage daily for one month at a dose of 4 mg / kg / day. Results: Pioglitazone significantly reduced the expression of CD36, LXRα, APOB100 genes in the drug treatment groups compared to the fatty liver group. Also, biochemical factors, TG, CHO, were significantly reduced compared to the fatty liver group after drug use in the drug treatment groups.